» Articles » PMID: 16393961

Galectin-3 and Galectin-1 Bind Distinct Cell Surface Glycoprotein Receptors to Induce T Cell Death

Overview
Journal J Immunol
Date 2006 Jan 6
PMID 16393961
Citations 217
Authors
Affiliations
Soon will be listed here.
Abstract

Galectins are a family of mammalian beta-galactoside-binding proteins that positively and negatively regulate T cell death. Extracellular galectin-1 directly induces death of T cells and thymocytes, while intracellular galectin-3 blocks T cell death. In contrast to the antiapoptotic function of intracellular galectin-3, we demonstrate that extracellular galectin-3 directly induces death of human thymocytes and T cells. However, events in galectin-3- and galectin-1-induced cell death differ in a number of ways. Thymocyte subsets demonstrate different susceptibility to the two galectins: whereas galectin-1 kills double-negative and double-positive human thymocytes with equal efficiency, galectin-3 preferentially kills double-negative thymocytes. Galectin-3 binds to a complement of T cell surface glycoprotein receptors distinct from that recognized by galectin-1. Of these glycoprotein receptors, CD45 and CD71, but not CD29 and CD43, appear to be involved in galectin-3-induced T cell death. In addition, CD7 that is required for galectin-1-induced death is not required for death triggered by galectin-3. Following galectin-3 binding, CD45 remains uniformly distributed on the cell surface, in contrast to the CD45 clustering induced by galectin-1. Thus, extracellular galectin-3 and galectin-1 induce death of T cells through distinct cell surface events. However, as galectin-3 and galectin-1 cell death are neither additive nor synergistic, the two death pathways may converge inside the cell.

Citing Articles

Cell-associated galectin 9 interacts with cytotoxic T cells confers resistance to tumor killing in nasopharyngeal carcinoma through autophagy activation.

Kam N, Lau C, Lau J, Dai X, Liang Y, Lai S Cell Mol Immunol. 2025; 22(3):260-281.

PMID: 39910335 PMC: 11868493. DOI: 10.1038/s41423-024-01253-8.


Ligands of CD6: roles in the pathogenesis and treatment of cancer.

Gurrea-Rubio M, Lin F, Wicha M, Mao-Draayer Y, Fox D Front Immunol. 2025; 15:1528478.

PMID: 39840036 PMC: 11747410. DOI: 10.3389/fimmu.2024.1528478.


Altered galectin-3 distribution and migratory function in the pre-diabetic non-obese diabetic mouse thymus.

Ramos T, Ventura A, Lemos J, Chammas R, Savino W, Carvalho-Pinto C Front Endocrinol (Lausanne). 2024; 15:1200935.

PMID: 39483979 PMC: 11524864. DOI: 10.3389/fendo.2024.1200935.


NPRL2 promotes TRIM16-mediated ubiquitination degradation of Galectin-3 to prevent CD8T lymphocyte cuproptosis in glioma.

Wang F, Yue J, Zhang M, Sun M, Luo X, Zhang H Cell Mol Life Sci. 2024; 81(1):424.

PMID: 39367988 PMC: 11456027. DOI: 10.1007/s00018-024-05454-2.


Galectin-1 is associated with hematopoietic cell engraftment in murine MHC-mismatched allotransplantation.

Shaikh A, Gangaplara A, Kone A, Almengo K, Kabore M, Ali M Front Immunol. 2024; 15:1411392.

PMID: 39351218 PMC: 11439684. DOI: 10.3389/fimmu.2024.1411392.